Emergent BioSolutions announced FDA approval for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray, designed to improve distribution efficiency and accessibility for high-volume partners. The new formats will be available through NARCANDirect® and complement recent approval of a NARCAN® carrying case, supporting the comp...

The global lipid nanoparticle (LNP) manufacturing market is valued at USD 565 million in 2026 and is expected to reach USD 2.24 trillion by 2034, growing at an 18.9% CAGR. North America currently dominates the market, while Asia-Pacific is experiencing notable expansion. Key growth drivers include mRNA vaccine development, precision medicine dema...

The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.

Emergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.

Emergent BioSolutions and Rocketvax have announced a strategic partnership, where Emergent will invest in Rocketvax and lead the U.S. manufacturing and commercialization of four of Rocketvax's pipeline candidates for infectious diseases, cancer, and autoimmune disorders.